<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sri G Yarlagadda, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Nickolas, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Darryl Quarles, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney transplant recipients are vulnerable to persistent hyperparathyroidism and other disorders of mineral and bone metabolism associated with chronic kidney disease (CKD).</p><p>This topic reviews recommendations regarding monitoring and treatment of hyperparathyroidism, hypercalcemia, and hypophosphatemia among kidney transplant candidates and recipients.</p><p>Other bone disorders that affect kidney transplant recipients, including osteoporosis and osteonecrosis, are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/100623.html" rel="external">"Kidney transplantation in adults: Bone disease after kidney transplantation"</a>.)</p><p>The pathogenesis of metabolic bone disease and the treatment of hyperparathyroidism in nontransplant patients with CKD are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H635254353"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Most patients with chronic kidney disease (CKD) develop some degree of secondary hyperparathyroidism by the time they initiate kidney replacement therapy (KRT). Secondary hyperparathyroidism occurs in response to multiple mineral metabolism–related abnormalities stemming from decreased glomerular filtration rate (GFR) that lead to persistent stimulation of parathyroid hormone secretion and adaptive parathyroid gland hyperplasia [<a href="#rid1">1</a>]. The pathophysiology of secondary hyperparathyroidism in patients with CKD is discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Overview'</a>.)</p><p>In patients with mild disease, secondary hyperparathyroidism resolves after kidney transplantation as a more normal GFR is restored [<a href="#rid2">2-7</a>]. However, persistent hyperparathyroidism is reported to occur in approximately 8 to 50 percent of patients following transplantation [<a href="#rid4">4,8-15</a>]. This is because of the persistence of structural changes in the parathyroid glands, such as hyperplasia and adenoma formation, despite removal of the initial stimuli for hyperparathyroidism [<a href="#rid4">4,16-19</a>].</p><p>The clinical manifestations of persistent hyperparathyroidism in the transplant recipient differ from those associated with hyperparathyroidism in nontransplant patients with CKD. In the transplant recipient, the clinical manifestations resemble primary hyperparathyroidism and are characterized by hypercalcemia and hypophosphatemia due to the effects of parathyroid hormone (PTH) on the kidney [<a href="#rid6">6</a>] (see <a class="local">'Clinical manifestations'</a> below). By contrast, nontransplant patients with CKD with hyperparathyroidism typically have hyperphosphatemia and hypocalcemia. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Disorders of calcium balance'</a>.)</p><p>Factors additional to hyperparathyroidism contribute to hypercalcemia and hypophosphatemia in transplant recipients [<a href="#rid6">6</a>]. Increased <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> production and resorption of soft-tissue calcium phosphate deposition can cause hypercalcemia [<a href="#rid4">4,10,20</a>]. Some patients have an increase in total plasma calcium because of an increase in the plasma albumin concentration (which is often due to better nutrition after transplantation). However, the increase in total calcium due to an increase in albumin is generally mild and of no clinical significance. Increased serum albumin raises the total plasma calcium concentration by increasing the albumin-bound fraction but has no effect on the physiologically important free or ionized calcium concentration. High-dose glucocorticoids may mask hypercalcemia due to effects that limit vitamin D-mediated gastrointestinal calcium absorption, with hypercalcemia variably manifested during tapering of the glucocorticoid dose. (See  <a class="medical medical_review" href="/z/d/html/845.html" rel="external">"Relation between total and ionized serum calcium concentrations"</a>.)</p><p>Hypophosphatemia after transplantation is caused by both persistent hyperparathyroidism and excess FGF-23 production [<a href="#rid11">11,21-24</a>]. FGF-23 is secreted by bone osteocytes and osteoblasts in response to <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>, increased dietary phosphate load, and PTH [<a href="#rid25">25-28</a>]. Patients with CKD have increased FGF-23 concentrations due to decreased phosphate clearance [<a href="#rid29">29-31</a>]. Markedly elevated FGF-23 levels before kidney transplantation may persist after transplant [<a href="#rid24">24</a>], but more commonly FGF-23 concentrations decline rapidly following transplantation [<a href="#rid32">32</a>].</p><p>The relative contribution of excess PTH and FGF-23 to phosphate wasting after transplantation depends on the timing of onset after transplantation. Both hyperparathyroidism and hyperphosphatonism (ie, increased FGF-23 secretion) may contribute to phosphate wasting during the early posttransplant period [<a href="#rid21">21-24</a>]. Persistent hyperparathyroidism, but not increased FGF-23, likely causes phosphate wasting that persists beyond one year [<a href="#rid11">11</a>].</p><p>Mammalian (mechanistic) target of rapamycin (mTOR) inhibitors may contribute to hypophosphatemia [<a href="#rid33">33</a>], though not all studies have shown this [<a href="#rid11">11</a>]. Higher doses of glucocorticoids have been associated with higher levels of FGF-23 [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H635254359"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The primary manifestations of persistent hyperparathyroidism after transplantation include hypercalcemia and hypophosphatemia [<a href="#rid7">7-9,14</a>]. However, some patients may have only an elevated parathyroid hormone (PTH) concentration, without other laboratory abnormalities.</p><p>Symptoms that are commonly observed in nontransplant patients with chronic kidney disease (CKD) who have severe hyperparathyroidism, including bone pain, pruritus, nephrolithiasis, and myopathy, are not generally observed among transplant recipients, since hyperparathyroidism is much less severe among transplant recipients. However, these symptoms may be manifested and associated with adverse outcomes if the hyperparathyroidism is severe and persistent.</p><p class="headingAnchor" id="H23776121"><span class="h2">Hypercalcemia</span><span class="headingEndMark"> — </span>Hypercalcemia is common following kidney transplantation [<a href="#rid6">6,14,35,36</a>]. In one study of 1165 transplant recipients, the prevalence of hypercalcemia from any cause (defined as total serum calcium &gt;10.5 mg/dL [2.6 mmol/L]) was 31 percent during the first year after transplantation and 12 percent at five years posttransplantation [<a href="#rid6">6</a>].</p><p>Symptomatic hypercalcemia most commonly occurs in the early posttransplant period, usually within the first three months [<a href="#rid35">35-37</a>].</p><p>Hypercalcemia causes direct vasoconstriction of the allograft and natriuresis-induced volume contraction. Severe hypercalcemia (plasma calcium concentration &gt;12.5 mg/dL [3.1 mmol/L]) can cause acute kidney injury and, rarely, calciphylaxis, in which vascular calcification leads to local ischemic necrosis [<a href="#rid4">4,38,39</a>]. (See  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a>.)</p><p class="headingAnchor" id="H23776236"><span class="h2">Hypophosphatemia</span><span class="headingEndMark"> — </span>Hypophosphatemia has been reported in 40 to 90 percent of patients in the early period following transplantation [<a href="#rid6">6,14,40</a>]. Hypophosphatemia usually decreases over time after transplantation, although it may persist in some patients [<a href="#rid6">6,14,40</a>]. In one study of 1165 recipients, the prevalence of hypophosphatemia (defined as serum phosphate concentration &lt;2.3 mg/dL [0.74 mmol/L]) was 40 percent in the first year and 11 percent during years 4 and 5 [<a href="#rid6">6</a>].</p><p>Severe hypophosphatemia (plasma phosphate levels &lt;1 to 1.5 mg/dL [0.32 to 0.48 mmol/L]) can cause muscle weakness, and longstanding hypophosphatemia can lead to osteomalacia (although the latter has not been a consistent finding). (See  <a class="medical medical_review" href="/z/d/html/847.html" rel="external">"Hypophosphatemia: Clinical manifestations of phosphate depletion"</a>.)</p><p class="headingAnchor" id="H635254561"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H505935298"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Persistent hyperparathyroidism has been associated with increased mortality [<a href="#rid41">41-43</a>]. In a multivariate analysis of 1614 transplant recipients identified from the Assessment of Lescol in Renal Transplantation (ALERT) trial, parathyroid hormone (PTH) values &gt;65 pg/mL were associated with an increase in all-cause mortality (hazard ratio [HR] 1.46, 95% CI 1.12-1.92) [<a href="#rid41">41</a>].</p><p>The mechanism underlying increased PTH-associated mortality is not known. High PTH levels and hypercalcemia promote vascular calcifications, which are associated with an increased posttransplant morbidity and mortality in kidney transplant patients [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H635254579"><span class="h2">Allograft loss</span><span class="headingEndMark"> — </span>Increased PTH is associated with increased graft loss [<a href="#rid41">41,43</a>]. In an analysis of data from the ALERT trial, PTH &gt;65 pg/mL (6.9 pmol/L) was associated with an 85 percent increase in death-censored graft loss (HR 1.85, 95% CI 1.41-2.42) [<a href="#rid41">41</a>].</p><p>The mechanism by which hyperparathyroidism contributes to graft loss is not known.</p><p class="headingAnchor" id="H3823141624"><span class="h2">Bone disease and fractures</span><span class="headingEndMark"> — </span>Uncontrolled hyperparathyroidism and hypercalcemia are risk factors for posttransplant bone disease, and hyperparathyroidism is associated with an increased risk of fractures [<a href="#rid40">40</a>]. In a study of 143 kidney transplant recipients, a PTH level &gt;130 pg/mL (13.8 pmol/L) at three months after transplantation was associated with a 7.5-fold increased risk of fracture over five years (HR 7.5, 95% CI 2.18-25.50) [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/100623.html" rel="external">"Kidney transplantation in adults: Bone disease after kidney transplantation"</a>.)</p><p class="headingAnchor" id="H2543237527"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The optimal treatment of hyperparathyroidism prior to transplantation may prevent persistent hyperparathyroidism after transplantation. The management of secondary hyperparathyroidism in patients with advanced chronic kidney disease (CKD), including those with end-stage kidney disease (ESKD) on dialysis, is discussed in more detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p></p><p>The approach to transplant candidates who have refractory hyperparathyroidism prior to transplantation varies among transplant centers. Almost all experts suggest parathyroidectomy for transplant candidates who have refractory hyperparathyroidism and moderate to severe symptoms (eg, bone pain, fractures, muscle pain, weakness), particularly if transplantation is not imminent. This approach is the same as the approach for nontransplant patients with ESKD. (See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p>Transplant nephrologists have differing recommendations for transplant candidates who have only mild or no symptoms. Prior to transplantation, independent of the absence or presence of symptoms, we generally refer for subtotal parathyroidectomy all transplant candidates who have an intact parathyroid hormone (PTH) ≥800 pg/mL (84.8 pmol/L) despite medical therapy. PTH concentrations &gt;800 pg/mL (84.8 pmol/L) have been associated with a &gt;80 percent risk of graft failure [<a href="#rid45">45</a>]. Intact PTH values above this threshold are unlikely to respond to vitamin D or active vitamin D derivatives [<a href="#rid46">46-49</a>]. In addition, as noted above, severe hyperparathyroidism is associated with delayed graft function, hypercalcemia/hypercalciuria, nephrolithiasis, hypophosphatemia, and decreased patient and allograft survival after transplantation. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Outcomes'</a> above.)</p><p>However, some transplant nephrologists do not perform parathyroidectomy prior to transplantation in asymptomatic patients, since, as noted above, hyperparathyroidism resolves in many, though not all, patients after transplantation [<a href="#rid6">6,50,51</a>]. (See <a class="local">'Pathophysiology'</a> above.)</p><p>Parathyroidectomy may be safer if performed prior to transplantation. Parathyroidectomy performed after transplantation has been associated with abrupt deterioration of kidney allograft function [<a href="#rid52">52,53</a>]. However, some data have shown that glomerular filtration rate (GFR) recovers in the long term [<a href="#rid54">54</a>], and allograft survival has not been shown to be lower in patients who have undergone parathyroidectomy after kidney transplant [<a href="#rid55">55,56</a>]. (See <a class="local">'Treatment'</a> below.)</p><p>For potential recipients of deceased-donor kidneys, but not living-donor kidneys, the decision regarding parathyroidectomy may depend on the anticipated time on the waiting list, which will vary based upon the geographic region. The indications for parathyroidectomy for patients who are expected to have a prolonged wait on the deceased-donor waiting list are the same as for patients who are not awaiting transplantation. (See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis", section on 'Potential indications for parathyroidectomy'</a>.)</p><p><a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">Cinacalcet</a> and <a class="drug drug_general" data-topicid="111821" href="/z/d/drug information/111821.html" rel="external">etelcalcetide</a> are commonly used among nontransplant candidate patients with ESKD who have refractory hyperparathyroidism. The use of these calcimimetic agents among transplant candidates varies among transplant centers. Some centers do not use calcimimetic agents in transplant candidates unless parathyroidectomy is contraindicated, as the use of cinacalcet prior to kidney transplantation has been associated with rebound hypercalcemia and hypophosphatemia when cinacalcet is discontinued at the time of transplantation [<a href="#rid57">57-59</a>]. However, other centers commonly use calcimimetic agents in transplant candidates and refer patients for parathyroidectomy only if hyperparathyroidism is refractory to medical therapy or there is medication intolerance. </p><p class="headingAnchor" id="H95063790"><span class="h1">MONITORING AFTER TRANSPLANT</span><span class="headingEndMark"> — </span>Among all kidney transplant recipients, we routinely monitor serum calcium, phosphorus, and parathyroid hormone (PTH) levels. Initially, serum calcium and phosphorus should be measured at each visit during the first year and PTH measured quarterly or more frequently in the presence of hypercalcemia or hypophosphatemia. Patients with a PTH concentration that is two to three times the upper limit of normal are considered to have persistent hyperparathyroidism. 25-hydroxyvitamin D should be measured posttransplant, with repeated testing determined by baseline values and therapeutic interventions.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Routine follow-up and laboratory monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/100623.html" rel="external">"Kidney transplantation in adults: Bone disease after kidney transplantation", section on 'Our approach to screening and monitoring kidney transplant candidates'</a>.)</p><p></p><p class="headingAnchor" id="H3990024016"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Our approach to the management of persistent hyperparathyroidism (ie, parathyroid hormone [PTH] concentration that is two to three times the upper limit of normal) after transplantation depends upon the patient's clinical presentation. As noted above, patients may present with hypercalcemia or hypophosphatemia. Some patients have an increased PTH concentration without either hypercalcemia or hypophosphatemia.</p><p class="headingAnchor" id="H3742581543"><span class="h2">Patients with hypercalcemia</span><span class="headingEndMark"> — </span>The approach to transplant recipients with hypercalcemia due to persistent hyperparathyroidism varies among centers. The severity of the hypercalcemia and PTH elevations determines the approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild to moderate hypercalcemia</strong> – In patients with hyperparathyroidism and mild to moderate hypercalcemia (ie, serum calcium levels &gt;0.5 to 1 mg/dL [0.12 to 0.25 mmol/L] than the upper limit of normal) posttransplant, we typically treat with <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> (30 mg daily) initially to prevent complications of increased calcium and PTH excess. We monitor serum calcium levels every two weeks and make dose adjustments at monthly intervals as needed. If the patient does not respond to cinacalcet by 6 to 12 months, we typically refer the patient for subtotal parathyroidectomy.</p><p></p><p class="bulletIndent1">Data from several observational studies and two small, randomized trials have shown that <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> reduces PTH levels and lowers serum calcium levels without any short-term adverse effects on allograft function [<a href="#rid60">60-68</a>]. However, one retrospective, single-center analysis of 133 patients with hyperparathyroidism after kidney transplantation found that parathyroidectomy was associated with a lower rate of allograft failure compared with cinacalcet (9 versus 33 percent, respectively) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">Cinacalcet</a> may reduce blood <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> concentrations. In a study of 14 kidney transplant patients that evaluated the interaction between cinacalcet and immunosuppressive therapy, one week of cinacalcet therapy induced a moderate but significant decrease in systemic exposure of tacrolimus, while <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> pharmacokinetics were unaffected [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe hypercalcemia</strong> – Parathyroidectomy is the preferred treatment for patients with persistent hyperparathyroidism and severe hypercalcemia (ie, serum calcium values &gt;12 mg/dL [3.0 mmol/L] or symptomatic hypercalcemia regardless of the level). In a multicenter, open-label, randomized trial of 30 patients with a serum calcium concentration &gt;10.5 mg/dL (2.6 mmol/L), subtotal parathyroidectomy was more likely to result in normocalcemia at 12 months compared with medical management with <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> (100 versus 67 percent) [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1">In the setting of hyperparathyroidism, the calcium concentration that provides an indication for treatment is variable. Initially (ie, within six months of transplantation), most clinicians rely on the presence of symptoms rather than the absolute calcium concentration to determine the approach. As noted, the predominant symptom/sign is polyuria with prerenal acute kidney injury, although, less commonly, calciphylaxis may occur. Even in the absence of symptoms, many clinicians refer for parathyroidectomy all patients with marked hypercalcemia (serum calcium values &gt;11 mg/dL [2.7 mmol/L]) that is present for &gt;6 months from time of transplantation. (See  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)", section on 'Hyperparathyroidism and vitamin D'</a>.)</p><p></p><p>Hypercalcemia that occurs in the absence of hyperparathyroidism may be treated the same as in nontransplant recipients. In particular, patients should ensure adequate fluid intake and avoid drugs that can cause hypercalcemia. (See  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia", section on 'Preferred approach'</a>.)</p><p class="headingAnchor" id="H2129043167"><span class="h2">Patients with hypophosphatemia</span><span class="headingEndMark"> — </span>The treatment of hypophosphatemia depends on the severity of hypophosphatemia, the PTH concentration, and the presence or absence of hypercalcemia [<a href="#rid71">71</a>].</p><p>Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild to moderate hypophosphatemia (1.0 to 2.3 mg/dL [0.32 to 0.74 mmol/L])</strong> – The treatment of mild or moderate hypophosphatemia depends on the PTH level. Among patients who have an increased PTH concentration (ie, approximately two to three times the upper limit of normal), we first treat the hyperparathyroidism. (See <a class="local">'Patients with increased PTH without hypercalcemia'</a> below.)</p><p></p><p class="bulletIndent1">If hypophosphatemia persists following successful treatment of high PTH, we increase the intake of phosphate-rich foods (<a class="graphic graphic_table graphicRef79877 graphicRef56081" href="/z/d/graphic/79877.html" rel="external">table 1A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe hypophosphatemia (&lt;1 mg/dL [&lt;0.32 mmol/L])</strong> – Most clinicians give oral phosphate supplements regardless of the PTH or calcium concentration (see  <a class="medical medical_review" href="/z/d/html/835.html" rel="external">"Hypophosphatemia: Evaluation and treatment"</a>). Vitamin D derivatives can also be used to raise phosphorus in this setting if patients are not hypercalcemic.</p><p></p><p class="bulletIndent1">Patients with severe hypophosphatemia and hyperparathyroidism are also referred for parathyroidectomy. (See <a class="local">'Patients with increased PTH without hypercalcemia'</a> below.)</p><p></p><p class="headingAnchor" id="H2575080630"><span class="h2">Patients with increased PTH without hypercalcemia</span><span class="headingEndMark"> — </span>The treatment of patients with persistent hyperparathyroidism (ie, two to three times the upper limit of normal) <strong>without</strong> hypercalcemia depends upon the 25-hydroxyvitamin D concentration:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the 25-hydroxyvitamin D concentration is below normal (ie, &lt;20 ng/mL [50 nmol/L]), we administer vitamin D3 (<a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">cholecalciferol</a>), 800 to 2000 units daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the 25-hydroxyvitamin D concentration is normal <strong>or</strong> if parathyroid hormone (PTH) is persistently elevated despite normalization of 25-hydroxyvitamin D levels with <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> therapy, which may occur if there is a significant degree of CKD, we treat with an activated vitamin D derivative, such as <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>. We start with a low dose (0.25 micrograms daily) and titrate up to a maximum of 0.5 micrograms per day. Serum calcium should be checked frequently (ie, every month) while titrating up the active vitamin D3 derivative dose. This approach is effective in most patients. Patients who develop hypercalcemia are treated as described above. (See <a class="local">'Hypercalcemia'</a> above.)</p><p></p><p>Treatment options for persistent hyperparathyroidism without hypercalcemia should lead to consideration of confounding factors, such as concurrent nutritional vitamin D deficiency, high-dose glucocorticoid treatment, low calcium intake, primary renal calcium wasting (loop diuretics), active bone uptake due to healing of renal osteodystrophy, or treatment with <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> that may lower calcium but not suppress PTH. A subtotal parathyroidectomy or addition of cinacalcet is <strong>not</strong> indicated to treat elevated PTH in the absence of hypercalcemia.</p><p class="headingAnchor" id="H2588874739"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H23740598"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Persistent hyperparathyroidism may occur in up to 50 percent of kidney transplant recipients. It has been associated with fractures, increased mortality, and decreased allograft survival. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathophysiology'</a> above and <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The primary manifestations of persistent hyperparathyroidism include hypercalcemia and hypophosphatemia. Symptoms observed in nontransplant patients with chronic kidney disease (CKD) such as bone pain, pruritus, and myopathy are rare. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The optimal treatment of hyperparathyroidism prior to transplantation is generally the safest approach to prevention of persistent hyperparathyroidism after transplantation. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – In all transplant recipients, we monitor serum calcium and phosphorus at each visit during the first year. We measure parathyroid hormone (PTH) quarterly or more frequently in the presence of hypercalcemia or hypophosphatemia. Patients with a PTH concentration that is two to three times the upper limit of normal are considered to have persistent hyperparathyroidism. 25-hydroxyvitamin D should be measured posttransplant, with repeated testing determined by baseline values and therapeutic interventions. (See <a class="local">'Monitoring after transplant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with hypercalcemia</strong> – The approach to transplant recipients with hypercalcemia due to persistent hyperparathyroidism varies among centers. Our approach is determined by the severity of the hypercalcemia and PTH elevations:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with <strong>mild to moderate</strong> hypercalcemia (ie, serum calcium levels &gt;0.5 to 1 mg/dL [0.12 to 0.25 mmol/L] above the upper limit of normal) and hyperparathyroidism, we suggest initial treatment with <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a>. If the patient does not respond to cinacalcet by 6 to 12 months, we typically refer the patient for subtotal parathyroidectomy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with <strong>severe </strong>hypercalcemia (ie, serum calcium values &gt;12 mg/dL [3.0 mmol/L] or symptomatic hypercalcemia regardless of the level) caused by elevated PTH, we suggest referral for subtotal parathyroidectomy. (See <a class="local">'Patients with hypercalcemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with hypophosphatemia</strong> – The treatment of hypophosphatemia due to persistent hyperparathyroidism depends upon the severity of hypophosphatemia, the PTH concentration, and the presence or absence of hypercalcemia. Our approach is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with <strong>mild to moderate </strong>hypophosphatemia (1.0 to 2.3 mg/dL [0.32 to 0.74 mmol/L]), treatment depends upon the PTH level. Among patients who have an increased PTH concentration, we first treat the hyperparathyroidism. If hypophosphatemia persists following successful treatment of high PTH, we increase the intake of phosphate-rich foods (<a class="graphic graphic_table graphicRef79877 graphicRef56081" href="/z/d/graphic/79877.html" rel="external">table 1A-B</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with <strong>severe </strong>hypophosphatemia (&lt;1 mg/dL [&lt;0.32 mmol/L]), we give oral phosphate supplements regardless of the PTH or calcium concentration. Vitamin D derivatives can also be used to raise phosphorus in this setting if patients are not hypercalcemic. Patients with severe hypophosphatemia and hyperparathyroidism are also referred for parathyroidectomy. (See <a class="local">'Patients with hypophosphatemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with persistent hyperparathyroidism without hypercalcemia</strong> – The treatment of patients with persistent hyperparathyroidism <strong>without</strong> hypercalcemia depends upon the 25-hydroxyvitamin D concentration. A subtotal parathyroidectomy or addition of <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> is <strong>not</strong> indicated to treat elevated PTH in the absence of hypercalcemia:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the 25-hydroxyvitamin D concentration is below normal (ie, &lt;20 ng/mL [50 nmol/L]), we administer vitamin D3 (<a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">cholecalciferol</a>), 800 to 2000 units daily.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the 25-hydroxyvitamin D concentration is normal <strong>or </strong>if PTH is persistently elevated despite normalization of 25-hydroxyvitamin D levels with <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> therapy, which may occur if there is a significant degree of CKD, we treat with an activated vitamin D derivative, such as <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>. (See <a class="local">'Patients with increased PTH without hypercalcemia'</a> above.)</p><p></p><p class="headingAnchor" id="H442575349"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David W Butterly, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6:913.</a></li><li><a class="nounderline abstract_t">Heaf JG. Bone disease after renal transplantation. Transplantation 2003; 75:315.</a></li><li><a class="nounderline abstract_t">Julian BA, Benfield M, Quarles LD. Bone loss after organ transplantation. Transplant Rev 1993; 7:82.</a></li><li><a class="nounderline abstract_t">Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 1992; 19:99.</a></li><li><a class="nounderline abstract_t">Bonarek H, Merville P, Bonarek M, et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999; 56:642.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004; 19:1281.</a></li><li><a class="nounderline abstract_t">Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients--a review. Am J Nephrol 2008; 28:246.</a></li><li><a class="nounderline abstract_t">Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54:1704.</a></li><li><a class="nounderline abstract_t">Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13:551.</a></li><li><a class="nounderline abstract_t">Borchhardt K, Sulzbacher I, Benesch T, et al. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007; 7:2515.</a></li><li><a class="nounderline abstract_t">Sirilak S, Chatsrisak K, Ingsathit A, et al. Renal phosphate loss in long-term kidney transplantation. Clin J Am Soc Nephrol 2012; 7:323.</a></li><li><a class="nounderline abstract_t">Reinhardt W, Bartelworth H, Jockenhövel F, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998; 13:436.</a></li><li><a class="nounderline abstract_t">Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17:268.</a></li><li><a class="nounderline abstract_t">Wolf M, Weir MR, Kopyt N, et al. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation 2016; 100:184.</a></li><li><a class="nounderline abstract_t">Walkenhorst Z, Maskin A, Westphal S, Fingeret AL. Factors Associated With Persistent Post-transplant Hyperparathyroidism After Index Renal Transplantation. J Surg Res 2023; 285:229.</a></li><li><a class="nounderline abstract_t">Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436.</a></li><li><a class="nounderline abstract_t">Arnold A, Brown MF, Ureña P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95:2047.</a></li><li><a class="nounderline abstract_t">Drüeke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48:259.</a></li><li><a class="nounderline abstract_t">Tillmann FP, Wächtler C, Hansen A, et al. Vitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post-transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years. Transplant Res 2014; 3:21.</a></li><li><a class="nounderline abstract_t">Bonnin MR, González MT, Huguet J, et al. 1,25-Dihydroxycholecalciferol as measured by a radioreceptor assay in normal subjects and patients after kidney transplantation. Clin Chem 1990; 36:389.</a></li><li><a class="nounderline abstract_t">Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006; 70:1486.</a></li><li><a class="nounderline abstract_t">Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006; 104:p23.</a></li><li><a class="nounderline abstract_t">Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006; 15:97.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Naesens M, Claes K, et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7:1193.</a></li><li><a class="nounderline abstract_t">Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18:1637.</a></li><li><a class="nounderline abstract_t">Lavi-Moshayoff V, Wasserman G, Meir T, et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299:F882.</a></li><li><a class="nounderline abstract_t">López I, Rodríguez-Ortiz ME, Almadén Y, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 80:475.</a></li><li><a class="nounderline abstract_t">Quinn SJ, Thomsen AR, Pang JL, et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 2013; 304:E310.</a></li><li><a class="nounderline abstract_t">Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205.</a></li><li><a class="nounderline abstract_t">Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65:1943.</a></li><li><a class="nounderline abstract_t">Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3:1829.</a></li><li><a class="nounderline abstract_t">Tataranni T, Biondi G, Cariello M, et al. Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am J Transplant 2011; 11:1656.</a></li><li><a class="nounderline abstract_t">Wesseling-Perry K, Tsai EW, Ettenger RB, et al. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant 2011; 26:3779.</a></li><li><a class="nounderline abstract_t">Muirhead N, Zaltman JS, Gill JS, et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin Transplant 2014; 28:161.</a></li><li><a class="nounderline abstract_t">Amin T, Coates PT, Barbara J, et al. Prevalence of Hypercalcaemia in a Renal Transplant Population: A Single Centre Study. Int J Nephrol 2016; 2016:7126290.</a></li><li><a class="nounderline abstract_t">Malyszko J, Koc-Zorawska E, Kozminski P, et al. Underrecognition and Underestimation of Disturbances in Calcium-Phosphate Balance in Kidney Transplant Recipients. Transplant Proc 2018; 50:1790.</a></li><li><a class="nounderline abstract_t">Ozdemir FN, Afsar B, Akgul A, et al. Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients. Transplant Proc 2006; 38:480.</a></li><li><a class="nounderline abstract_t">Çeltik A, Şen S, Yılmaz M, et al. The effect of hypercalcemia on allograft calcification after kidney transplantation. Int Urol Nephrol 2016; 48:1919.</a></li><li><a class="nounderline abstract_t">Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 2013; 13:2653.</a></li><li><a class="nounderline abstract_t">Pihlstrøm H, Dahle DO, Mjøen G, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation 2015; 99:351.</a></li><li><a class="nounderline abstract_t">Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22:956.</a></li><li><a class="nounderline abstract_t">Baia LC, Humalda JK, Vervloet MG, et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8:1968.</a></li><li><a class="nounderline abstract_t">Hernández D, Rufino M, Bartolomei S, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005; 67:2015.</a></li><li><a class="nounderline abstract_t">Roodnat JI, van Gurp EA, Mulder PG, et al. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation 2006; 82:362.</a></li><li><a class="nounderline abstract_t">Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23:229.</a></li><li><a class="nounderline abstract_t">Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66:2010.</a></li><li><a class="nounderline abstract_t">Sharma J, Raggi P, Kutner N, et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 2012; 214:400.</a></li><li><a class="nounderline abstract_t">Komaba H, Taniguchi M, Wada A, et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 88:350.</a></li><li><a class="nounderline abstract_t">Schmid T, Müller P, Spelsberg F. Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997; 12:2393.</a></li><li><a class="nounderline abstract_t">Ferreira GF, Montenegro FL, Machado DJ, et al. Parathyroidectomy after kidney transplantation: short-and long-term impact on renal function. Clinics (Sao Paulo) 2011; 66:431.</a></li><li><a class="nounderline abstract_t">Rostaing L, Moreau-Gaudry X, Baron E, et al. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997; 47:248.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005; 20:1714.</a></li><li><a class="nounderline abstract_t">Tseng PY, Yang WC, Yang CY, Tarng DC. Long-term Outcomes of Parathyroidectomy in Kidney Transplant Recipients with Persistent Hyperparathyroidism. Kidney Blood Press Res 2015; 40:386.</a></li><li><a class="nounderline abstract_t">Kandil E, Florman S, Alabbas H, et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci 2010; 339:420.</a></li><li><a class="nounderline abstract_t">Frey S, Goronflot T, Blanchard C, et al. Impact of parathyroidectomy on kidney graft function in post-transplant tertiary hyperparathyroidism: a comparative study. Langenbecks Arch Surg 2022; 407:2489.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Sprangers B, Lerut E, et al. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clin Transplant 2012; 26:393.</a></li><li><a class="nounderline abstract_t">Barros X, Fuster D, Paschoalin R, et al. Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation. Endocrine 2015; 49:267.</a></li><li><a class="nounderline abstract_t">Sharma AK, Masterson R, Holt SG, et al. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients. Nephrology (Carlton) 2016; 21:46.</a></li><li><a class="nounderline abstract_t">Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20:1311.</a></li><li><a class="nounderline abstract_t">Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20:1315.</a></li><li><a class="nounderline abstract_t">Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1:323.</a></li><li><a class="nounderline abstract_t">Szwarc I, Argilés A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82:675.</a></li><li><a class="nounderline abstract_t">Leca N, Laftavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6:2391.</a></li><li><a class="nounderline abstract_t">El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83:546.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Cooper K, Holdaas H, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 2014; 14:2545.</a></li><li><a class="nounderline abstract_t">Cruzado JM, Moreno P, Torregrosa JV, et al. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism. J Am Soc Nephrol 2016; 27:2487.</a></li><li><a class="nounderline abstract_t">Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg 2017; 104:804.</a></li><li><a class="nounderline abstract_t">Finnerty BM, Chan TW, Jones G, et al. Parathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival. Surgery 2019; 165:129.</a></li><li><a class="nounderline abstract_t">Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008; 23:1048.</a></li><li><a class="nounderline abstract_t">Ambühl PM, Meier D, Wolf B, et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999; 34:875.</a></li></ol></div><div id="topicVersionRevision">Topic 7299 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21454719" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12589151" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bone disease after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bone loss after organ transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739106" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Musculoskeletal complications after renal transplantation: pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432404" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reduced parathyroid functional mass after successful kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993493" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989497" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Abnormal bone and mineral metabolism in kidney transplant patients--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9844148" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Persistent secondary hyperparathyroidism after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805187" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Calcium metabolism and skeletal problems after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17725680" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22134626" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renal phosphate loss in long-term kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9509459" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sequential changes of biochemical bone parameters after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780679" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hyperparathyroidism and long-term bone loss after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26177089" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36709541" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Factors Associated With Persistent Post-transplant Hyperparathyroidism After Index Renal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8397225" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738171" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7564087" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The pathogenesis of parathyroid gland hyperplasia in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25606342" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post-transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2302793" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 1,25-Dihydroxycholecalciferol as measured by a radioreceptor assay in normal subjects and patients after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941023" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16691036" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481873" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Post-renal transplantation hypophosphatemia: a review and novel insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17359508" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494882" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : How fibroblast growth factor 23 works.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20685823" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21525854" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23233539" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917335" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086938" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : FGF-23 in patients with end-stage renal disease on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633152" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922992" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21672148" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21441401" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24329899" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27493801" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prevalence of Hypercalcaemia in a Renal Transplant Population: A Single Centre Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30056901" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Underrecognition and Underestimation of Disturbances in Calcium-Phosphate Balance in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549153" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27522659" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The effect of hypercalcemia on allograft calcification after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034142" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25594550" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436289" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929933" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840052" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical impact of preexisting vascular calcifications on mortality after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906034" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311080" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pathogenesis of secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496173" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Survival following parathyroidectomy among United States dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22463880" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Improved long-term survival of dialysis patients after near-total parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786097" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9394329" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21552668" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Parathyroidectomy after kidney transplantation: short-and long-term impact on renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9128792" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919696" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26184764" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term Outcomes of Parathyroidectomy in Kidney Transplant Recipients with Persistent Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20234299" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35596781" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of parathyroidectomy on kidney graft function in post-transplant tertiary hyperparathyroidism: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22007637" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25154517" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26072678" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941846" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941845" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699223" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Improvement in hypercalcemia with cinacalcet after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969292" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16869807" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353771" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25225081" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26647424" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28518414" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Systematic review of surgical and medical treatment for tertiary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415867" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Parathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17956893" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561144" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
